‘It’s still working’: More are living with cancer as era of targeted drugs takes hold
Advancements in targeted cancer therapies are leading to record survival rates for patients. Personalized medicine, which focuses on specific genetic mutations, is enhancing treatment success and allowing many individuals to live active lives despite their diagnoses. Ongoing research aims to further improve cancer care through comprehensive genomic profiling.
- ▪The American Cancer Society reports that 18 million Americans who have had cancer are currently alive.
- ▪Survival rates for cancer patients have increased significantly, with seven out of ten surviving at least five years.
- ▪Recent studies show a 25 percent drop in cancer deaths among people aged 15 to 49 since 1990.
Opening excerpt (first ~120 words) tap to expand
‘It’s still working’: More are living with cancer as era of targeted drugs takes holdSign up now: Get ST's newsletters delivered to your inboxMenta “Steve” Wallace and his wife, Jo Linda, at their home in Texas. Menta is taking the experimental pancreatic cancer drug daraxonrasib.PHOTO: REUTERSPublished Jun 03, 2026, 08:55 PMUpdated Jun 03, 2026, 08:59 PMListenSummariseAdvances in targeted drugs and understanding cancer’s genetic basis mean record survival rates.Personalised medicine, targeting specific genetic mutations like HER2 or EGFR, is improving drug success, helping patients overcome resistance and extend life.Cancer patients are living active lives due to these advances.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Straits Times — World.